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Abstract
Drug resistance, one of the major obstacle in the successful anticancer therapy, can be observed at the outset of therapy (intrinsic
resistance) or after exposure to the antitumor agent (acquired resistance). To gain a better insight into the mechanisms of intrinsic
resistance we have analyzed two human cell types derived from untreated tumors: MCF-7 breast cancer and A549 non small cell
lung cancer (NSCLC). We have examined: the cytotoxic eﬀect induced by doxorubicin (DOX); the time course of drug accumula-
tion by ﬂow cytometry and intracellular drug distribution by confocal microscopy; the expression and distribution of proteins
related to anthracycline resistance, such as P-gp (P-glycoprotein), MRP1 (multidrug resistance-associated protein) and LRP (lung
resistance-related protein). The cytotoxicity assays showed that A549 cells were less sensitive than MCF-7 cells to the DOX treat-
ment in agreement with the diﬀerent DOX uptake. Moreover, while in A549 cells DOX was mostly located in well deﬁned intra-
cytoplasmic vesicles, in MCF-7 cells it was mainly revealed inside the nuclei. The analysis of P-gp and MRP expression did not
show signiﬁcant diﬀerences between the two cell lines while a high expression of LRP was detected at the nuclear envelope and
cytoplasmic levels in A549 cells. These ﬁndings suggest that the lower sensitivity to DOX treatment showed by lung carcinoma cells
could be ascribed to drug sequestration by LRP inside the cytoplasmic compartments. # 2002 Elsevier Science Ltd. All rights
reserved.
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1. Introduction
Successful chemotherapeutic treatment of tumors is
often seriously hampered by their poor response to
anticancer drugs. In fact, tumor cells can be insensitive
to drug treatment at the outset of therapy, thus exhibiting
an intrinsic resistant phenotype (Childs and Ling, 1994).
The mechanisms responsible for intrinsic drug resis-
tance are still poorly understood. It is well known that
tumor cells exposed to antineoplastic agents may
develop, both in vivo and in vitro, a multidrug resistant
(MDR) phenotype, which is generally associated with
altered expression of drug transporter proteins, such as
P-glycoprotein (P-gp) (Gottesman and Pastan, 1993;
Shapiro and Ling, 1995) and the family of multidrug
resistance-associated proteins (MRPs) (Cole et al., 1992;
Berger et al., 1997). These proteins act as ATP-depen-
dent molecular pumps, which extrude a number of
antitumor drugs from the cell, thus decreasing their
concentrations at intracellular targets. It is generally
believed that an intrinsic MDR phenotype is caused by
multiple mechanisms; recent evidence suggests that
changes in transport proteins may also contribute to
this more elusive form of drug resistance (Berger et al.,
2000; Meschini et al., 2000). Recently, overexpression of
a 110 kDa vesicular protein, termed lung resistance-
related protein (LRP), has been demonstrated in a
number of tumor cell lines intrinsically resistant to
chemotherapeutic drugs (Laurencot et al., 1997). LRP
has been found to be identical with the human major
vault protein (MVP), which is the major component of
vaults (Scheﬀer et al., 1995; Izquierdo et al., 1996).
Vaults are multisubunit complexes of ribonucleoprotein
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particles exhibiting an octagonal barrel-shaped
structure, with protruding caps and an invaginated
waist. These structures are highly conserved among
eukaryotes, suggesting that they are essential for cell
function (Kedersha et al., 1990); however, their physi-
ological role in normal tissues and in intrinsic or
acquired drug resistance is yet to be deﬁned. Vaults are
mainly located within the cytoplasm, where they exhibit
a punctate distribution, while a minor fraction concurs
to the formation of nuclear pore complexes. Therefore,
based on their subcellular localization, vaults have been
implicated in vesicular and nucleocytoplasmic drug
transport (Scheﬀer et al., 1995). In fact, the entrapment
of drugs into vesicular compartments and decreased
nuclear/cytoplasmic ratios have been observed in some
MDR cell lines overexpressing LRP (Dietel et al., 1990;
Schuurhuis et al., 1991).
While one or more drug transport proteins may con-
tribute to the intrinsic MDR phenotype, a more general
mechanism for drug resistance has recently emerged and
has gained increasing popularity with tumor cell biolo-
gists, namely the inability of cells to undergo apoptosis,
which is now generally acknowledged as leading to cell
death upon exposure to anticancer agents. Intrinsic or
acquired defects in the apoptotic machinery could
therefore profoundly alter the therapeutic outcome and
have become an area of active research.
To investigate the mechanisms responsible for intrin-
sic drug resistance, we have analyzed two diﬀerent
human cell lines, MCF-7 (breast carcinoma) and A549
(non small cell lung carcinoma, NSCLC). Both cell lines
were derived from untreated tumors and their response
to chemotherapeutic agents is a fair reproduction of the
clinical behaviour of the tumor types from which they
originated. Breast adenocarcinomas, which represent
the most common form of cancer in women, usually
respond to pharmacological and endocrine treatments
at the outset of therapy, even though they frequently
progress from hormone-dependent to hormone-inde-
pendent growth, and very easily acquire MDR and
metastatic properties (Clarke et al., 1990; Leonessa et
al., 1992). Lung cancers are classiﬁed in 2 main histolo-
gical groups, small cell lung cancers (SCLCs) and non
small cell lung cancers (NSCLCs). The latter are espe-
cially characterized by a poor prognosis (Cole et al.,
1992; Doyle, 1993); NSCLCs are frequently chemore-
sistant from diagnosis and in vitro NSCLC cells often
exhibit an intrinsic multidrug resistant phenotype
(Scheper et al., 1993). Only low amounts of the MDR1
gene product have been detected in unselected NSCLC
cell lines, suggesting that other mechanisms could be
involved in the intrinsically resistant phenotype (Doyle,
1993). Overexpression of LRP, originally observed in a
NSCLC cell line selected for resistance against doxo-
rubicin (DOX) and subsequently detected in other cell
lines of diﬀerent histogenetic origin (Scheper et al.,
1993; Scheﬀer et al., 1995), has been proposed to play a
major role in this phenomenon.
In the present study, we have examined: (1) the cyto-
toxic eﬀect induced by DOX treatment in MCF-7 and
A549 cells and the ability of the cells to undergo apop-
tosis in response to drug treatment; (2) the time course
of drug accumulation by ﬂow cytometric analysis and
the intracellular distribution of the drug by laser con-
focal microscopy; and (3) the intracellular levels and
distribution of transport proteins related to anthracy-
cline resistance, including P-gp, MRP1 and LRP.
Our data seem to indicate that the lower sensitivity to
doxorubicin observed in A549 non small lung cancer
cells is mainly due to the high intracellular expression of
LRP. Moreover, the association of LRP with intrinsic
drug resistance in vitro has been pointed out and the
potential value of this protein as marker of clinical drug
resistance has been argued.
2. Materials and methods
2.1. Cell cultures
Two human drug sensitive cell lines, A549 (non small
cell lung cancer, NSCLC) and MCF-7 (breast adeno-
carcinoma) were used. These cells grow as monolayer in
RPMI 1640 medium supplemented with 10% FCS, 1%
l-glutamine and 0.1% gentamycin at 37 C in a 5%
CO2 humidiﬁed atmosphere in air.
2.2. Cytotoxicity studies
Growth inhibition by DOX was determined by the
MTT assay (Alley et al., 1988). Approximately 3000–
5000 cells per well were seeded onto 96-well plates and
allowed to attach for 24 h before treatment with a range
of drug concentrations for 5 days. A 5-day exposure
time was chosen to allow the cells to grow in the pre-
sence of the drug for at least two doubling times. Initial
cell densities were adjusted accordingly to obtain a 80–
90% conﬂuent monolayer in control wells at the end of
the experiment.
2.3. Scanning electron microscopy
For scanning electron microscopy (SEM) studies, cells
grown on coverslips were ﬁxed with 2.5% glutar-
aldehyde in 0.1 m cacodylate buﬀer (pH 7.3) added with
2% sucrose at room temperature for 20 min. After
postﬁxation with 1% OsO4 in 0.1 m cacodylate buﬀer
(pH 7.3) at room temperature for 30 min, cells were
dehydrated through graded ethanol concentrations, cri-
tical point-dried in CO2 (CPD 030 Baltec device, Bal-
zers, Liechtenstein) and gold coated by sputtering (SCD
040 Balzers device). The samples were then examined
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with a Cambridge Stereoscan 360 scanning electron
microscope (Cambridge Instruments, Cambridge, UK).
2.4. Apoptosis evaluation by Hoechst labelling
Cell lines were exposed for 24, 48 and 72 h to 2 mm
DOX, rinsed twice with PBS, ﬁxed with 3% paraf-
ormaldehyde in PBS for 10 min and then stained with 5
mg/ml Hoechst 33342 (Molecular Probes, Interchim,
Asnie`res, France) to evaluate morphological DNA fea-
tures. Fluorescence microscopy analysis was performed
with a Nikon Microphot-SA ﬂuorescence microscope
(Nikon, Tokyo, Japan) with an excitation and emission
wavelenghts of 330–385 nm and 420–460 nm, respec-
tively. Cells were classiﬁed as ‘‘normal’’ when the nuclei
were intact and exhibited uncondensed chromatin, as
‘‘apoptotic’’ when perinuclear condensed chromatin or
apoptotic bodies were revealed. All analyses were per-
formed by morphological examination of at least 100
cells per sample and repeated at least twice.
2.5. MAb reagents
For ﬂow cytometric and ﬂuorescence microscopy
analyses, intracytoplasmic P-gp was labelled with MAb
MRK16 (Kamiya Biomedical Company, Thousand
Oaks, CA), a mouse IgG2a immunoglobulin that recog-
nizes a conformational epitope distributed on the 1st
and 4st loops of P-gp molecule. The concentration used
for these studies was 10 mg/ml.
For MRP1 detection, MAb MRPr1 (Kamiya), a rat
IgG2a immunoglobulin which reacts with an internal epi-
tope of MRP1 and does not cross-react with the human
MDR1 gene product (Flens et al., 1994), was employed.
The optimal concentration for this antibody in ﬂow cyto-
metry and immunocytochemistry studies was 1 mg/ml.
For LRP detection, MAbs LRP-56 (IgG2b; Signet
Laboratories Inc., Dedham, MA) and LRP-42 (IgG1;
Transduction Laboratories, Lexington, KY) directed
against diﬀerent epitopes of LRP (Scheper et al., 1993;
Berger et al., 1997) were employed. These MAbs were
used at a ﬁnal working concentration of 0.2 mg/ml and
0.5 mg/ml, respectively. The control isotype antibodies
used were obtained from Sigma (Sigma Chemical Com-
pany, St. Louis, MO).
2.6. Confocal microscopy
The analysis of the intracellular distribution of DOX
was carried out by confocal laser scanning microscopy
by taking advantage of the intrinsic ﬂuorescence of the
drug. The observations were performed on living cells,
grown on 13-mm glass coverslips, mounted on micro-
scope slides in the presence of the growth medium and
analysed under oil immersion objective. In order to
avoid cell damage, the image acquisitions were quickly
made on several cells present on diﬀerent coverslips for
each sample, acquiring signals coming from one ﬁeld
per coverslip. The samples were incubated with 2 mm
DOX for 10 min, 30 min, 1 h and 4 h at 37 C. The cells
were also observed without any treatment, under the
same instrumental conditions, in order to detect the
spontaneous autoﬂuorescence. A very weak and diﬀuse
ﬂuorescence was emitted by untreated cells.
To detect intracellular expression of LRP, cells were
ﬁxed with freshly prepared 3.7% formaldehyde in PBS
(pH 7.4) for 10 min at room temperature and subse-
quently permeabilized with 0.5% Triton X-100 (Sigma)
in PBS for 5 min. After washings in PBS, the samples
were labelled either with MAb LRP-56 or MAb LRP-42
and subsequently with a goat anti-mouse IgG ﬂuor-
escein-conjugate (Sigma). Incubations with primary and
secondary antibodies were performed for 30 min at 4 C
in PBS containing 1% bovine serum albumin (BSA,
Sigma), 10% fetal calf serum and 10% human AB
serum (Sigma).
The observations were carried out with a Sarastro
2000 confocal laser scanning microscope (Molecular
Dynamics, Sunnyvale, CA) equipped with a 25-mW
argon laser coupled to an epiﬂuorescence Nikon Opti-
phot microscope with a 60 oil-immersion objective lens
(NA=1.4). The excitation and emission wavelengths
employed were 488 nm and 510 nm, respectively. The
images were acquired in average accumulation mode
(two scans in each section), with an image size of
10241024 pixels and pixel size of 0.08 mm. The optical
sectioning was carried out with 0.9 mm step size.
2.7. Flow cytometry
All ﬂow cytometric analyses were carried out on cell
suspensions (106 cells/ml) obtained by incubating
monolayer cell cultures with EDTA and trypsin.
To detect intracellular expression of P-gp and LRP,
cell suspensions were ﬁxed with 2% paraformaldehyde
in PBS for 10 min at 4 C. The samples were then per-
meabilized by adding 0.05% Triton X-100 for 10 min at
4 C. Incubations with the primary (MRK16, LRP-56,
LRP-42) and secondary (goat anti-mouse IgG ﬂuor-
escein-conjugate) antibodies were performed for 30 min
at 4 C in PBS containing 1% BSA, 10% fetal calf
serum and 10% human AB serum. For negative con-
trols, cells were labelled with mouse isotypic globulins.
For MRP1 detection with MAb MRPr1, cells were
permeabilized in 10% (v/v) lysing solution G (Becton
Dickinson, Mountain View, CA) in dH2O and incu-
bated for 15 min in PBS/BSA containing 1% normal
goat serum. Cells were then incubated for 45 min at 4 C
with the MRPr1 antibody; after washings with PBS,
cells were incubated with a goat anti-rat IgG ﬂuor-
escein-conjugate. For negative controls, cells were incu-
bated with rat isotypic globulins.
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Time course studies of drug accumulation were per-
formed on MCF-7 and A549 cells treated with 2 mm
DOX for 1 and 4 h. At the end of treatments, cells were
washed with ice-cold Hank’s balanced salt solution
(HBSS, Sigma), detached with EDTA and trypsin,
resuspended in ice-cold PBS and immediately analyzed
for DOX content.
Fluorescence was analyzed with a FACScan ﬂow cyt-
ometer (Becton Dickinson) equipped with a 15-mW,
488 nm, air-cooled argon ion laser. The ﬂuorescence
emissions were collected through a 530 nm band-pass
ﬁlter for ﬂuorescein and a 575 nm band-pass ﬁlter for
DOX and acquired in log mode. For DOX accumula-
tion studies, drug ﬂuorescence intensity was expressed
as the mean ﬂuorescence channel (MFC) calculated
from the ﬂow cytometric proﬁles by the Cell Quest
software (Becton Dickinson).
For quantitative evaluation of P-gp, MRP and LRP
expression, protein content was expressed in arbitrary
units (A.U.) and obtained as the ratio of the MFC of
labelled samples on the MFC of negative controls.
2.8. Immunoprecipitation
Approximately 107 cells were washed 3 times in cold
PBS and incubated for 30 min on ice in lysis buﬀer [PBS
with 1mm EDTA, 1 mm phenylmethylsulfonyl ﬂuoride
(Sigma) and 1% Nonidet P-40 and protease inhibitor
coktail tablet (Boheringer Mannheim, Germany)].
Nuclei and unsolubilized cell membranes were removed
by centrifugation at 14,000 rpm for 10 min. Super-
natants were aliquoted into 1.5 ml conich tubes supple-
mented with 1% non fat milk powder and precleared
with 100 ml protein A/G Plus-Agarose (diluted 1:1 in
PBS, Santa Cruz Biotechnology, CA) to reduce non-
speciﬁc binding. The samples were spinned at 14,000
rpm for 15 min at 4 C; supernatants were then incu-
bated with 15 ml of undiluted LRP-56 (1 mg/ml) or with
an equivalent amount of an irrelevant mouse IgG2b
antibody for 2 h at 4 C. Immune complexes were pre-
cipited by further incubation for 1 h at 4 C with 100 ml
protein A/G Plus-Agarose (1:1 in PBS). Precipitates
were washed twice with lysis buﬀer supplemented with
0.1% sodium dodecyl sulphate and four times with PBS,
and resuspended in 50 ml sample buﬀer [200 mM Tris–
HCL (pH 6.8), 1% 2-mercaptoethanol, 8% sodium
dodecylsulfate, 10% glycerol and 0.05% bromophenol
blue]. After centrifugation, supernatants were analyzed
on 7.5% SDS–PAGE. Gel was stained with Silver Stain
Plus kit (Bio-Rad Laboratories, Richmond, CA)
according to the manufacturer’s instructions.
2.9. Statistical analysis
The values reported in the ﬁgures are the means
standard deviation (S.D.) from four to six indepen-
dent experiments. Statistical analyses were performed
using Student’s t-test. A P value lower than 0.05 was
considered signiﬁcant (asterisk in table and ﬁgures).
3. Results
3.1. Morphological characterization by SEM
Scanning electron microscopy of exponentially growing
(about 48 h from seeding) MCF-7 and A549 cell mono-
layers evidenced morphological diﬀerences between the
two cell lines. Breast carcinoma cells (MCF-7) appeared
to be heterogeneous in size and shape, and their surface
was covered by abundant, densely packed microvilli
(Plate 1a); a number of roundish cells poorly adherent
to the substratum was detected. Conversely, lung cancer
cells (A549) were quite homogeneous in morphology
(Plate 1b). Most of A549 cells appeared to be large,
ﬂattened, well adherent to the substratum, with short
and sparse microvilli projecting from the cell surface.
Plate 1. Scanning electron micrographs of (a) MCF-7 and (b) A549
cells. Breast carcinoma cells appeared to be heterogeneous in size and
shape while lung cancer cells showed to be large, ﬂattened with short
and sparse microvilli (800).
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3.2. Drug sensitivity
The cytotoxic eﬀect of doxorubicin on the two cell
lines, expressed as the IC50 values, has been determined
by the MTT assay. Table 1 shows the mean IC50 values
(S.D.) obtained from four independent experiments.
In agreement with the low drug sensitivity of NSCLC
cells, A549 cells were about 40 times more resistant to
DOX treatment than MCF-7 cells.
3.3. Detection of apoptotic nuclei
Fluorescence microscopy observations of control and
DOX-treated cells after Hoechst staining were carried
out. The quantitative analysis revealed that the percen-
tage of apoptotic cells (condensed chromatin and/or
fragmented nuclei) after 72 h of treatment with 2 mm
DOX was signiﬁcantly higher in MCF-7 cells (about
35%) than in A549 cells (less than 10%) (Plate 2a).
Plate 2 (b and c) show MCF-7 and A549 cells, respec-
tively, in which the diﬀerent response of the two cell
types is well evident.
3.4. DOX accumulation and distribution
To verify whether the lower sensitivity to DOX evi-
denced by the MTT assay in A549 cells with respect to
MCF-7 cells was due to a reduced intracellular drug
concentration, the time course of drug accumulation
was determined by ﬂow cytometry and the intracellular
drug distribution was analyzed by confocal microscopy.
No signiﬁcant diﬀerence in DOX accumulation between
the two cell lines was observed after 1 h of treatment
Table 1
Mean IC50 values
Cell lines IC50
MCF-7 12.783.11
A549 514.0988.64*
Drug sensitivity, obtained by the MTT assay, was expressed as the
drug concentration that inhibits 50% of cell growth (IC50). 24 h after
seeding, cells were treated with a range of DOX concentrations for 5
days. A549 cells showed to be about 40 times more resistant to DOX
than MCF-7 cells (*P<0.001).
Plate 2. Apoptosis evaluation after Hoechst labelling. Cells were treated with 2 mm DOX for 72 h, ﬁxed with paraformaldehyde and stained with 5
mg/ml Hoechst 33342. (a) The percentage of apoptotic cells (y-axis), calculated by morphological examination of at least 100 cells per sample, was
much higher in MCF-7 treated cells (**P<0.01 when compared to the control) than in A549 treated cells (*P<0.05 when compared to the control).
Cells were classiﬁed as ‘‘normal’’ when the nuclei were intact and exhibited uncondensed chromatin, as ‘‘apoptotic’’ when perinuclear condensed
chromatin or apoptotic bodies were revealed. Fluorescence microscopy analysis showed the diﬀerent response between (b) MCF-7 and (c) A549 cells
(b, 1500; c, 800).
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with 2 mm DOX, while after 4 h MCF-7 cells showed
signiﬁcantly higher intracellular levels of the drug than
A549 cells (Fig. 1).
Confocal microscopy revealed a diﬀerent DOX dis-
tribution between the two cell lines during the early
phase of the uptake (Plate 3). After 10 min of treatment,
MCF-7 cells showed a diﬀuse ﬂuorescent signal which
did not seem to associate with speciﬁc intracellular
structures (Plate 3a). In contrast, while A549 cells
exhibited a lower total ﬂuorescence intensity than
MCF-7, this was mainly concentrated in vesicular
structures in the perinuclear region (Plate 3b). The pre-
sence of DOX in intracytoplasmic compartments sug-
gested that the anthracycline was localized in
cytoplasmic organelles prior to its access to the nucleus.
After 30 min of treatment, higher DOX amounts were
already detectable in the nuclei of MCF-7 cells (Plate
3c), as compared to A549 cells (Plate 3d). After 4 h of
treatment, DOX was located inside the nuclei and in the
perinuclear region of both cell lines (Plate 3e and f),
even if a higher ﬂuorescent signal could be detected in
MCF-7 cells, conﬁrming ﬂow cytometric determination.
3.5. P-gp, MRP1 and LRP expression
Flow cytometric and immunoﬂuorescence microscopy
analysis of the expression of the two main drug trans-
porters, P-gp and MRP1, carried out on living cells,
revealed that both MCF-7 and A549 cells were com-
pletely negative for surface labelling of the two trans-
porters. When ﬂow cytometric analysis was carried out
on ﬁxed and permeabilized cells, similar levels of intra-
cytoplasmic P-gp and MRP1 (Fig. 2a and b, respec-
tively) could be detected in the two cell types. In
contrast, expression and distribution of the major vault
protein LRP were found to be quite diﬀerent between
MCF-7 and A549 cells (Plate 4). Immunoprecipitation
Fig. 1. Flow cytometric analysis of DOX accumulation in MCF-7 and
A549 cells. Samples were treated with 2 mm DOX for 1 and 4 h,
washed with cold HBSS, resuspended in cold PBS and analyzed for
drug content. On the y-axis the mean ﬂuorescence channel (MFC)
represents the drug ﬂuorescence intensity coming from the cells. After
1 h of treatment, no signiﬁcant diﬀerence in DOX content could be
revealed between the two cell lines, while after 4 h MCF-7 cells accu-
mulated higher amounts of drug with respect to A549 cells (*P<0.05).
Fig. 2. Flow cytometric analysis of (a) P-gp and (b) MRP expression on MCF-7 and A549 cells. Samples were ﬁxed, permebilized and incubated
with MAb MRK16 and a goat anti-mouse IgG ﬂuorescein-conjugate secondary antibody (for P-gp labelling) and with MAb MRPr1 and a goat
anti-rat IgG ﬂuorescein-conjugate secondary antibody (for MRP labelling). On the y-axis, protein content was expressed in arbitrary units (A.U.)
and calculated as the ratio of the MFC of labelled samples on the MFC of negative controls, obtained by incubating the cells with mouse or rat
isotypic globulins. No signiﬁcant diﬀerence in P-gp and MRP expression could be detected between the two cell lines.
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with the anti-LRP MAb LRP-56 revealed the presence
of a 110 kDa protein in both cell lines (Plate 4a). How-
ever, ﬂow cytometric analysis of MAb LRP-56-labelled
samples showed that the ﬂuorescent signal obtained was
about twice as intense for A549 cells than for MCF-7
cells (Plate 4b). LSCM observations, carried out under
the same immunolabelling conditions, revealed that
LRP was virtually undetectable in the more sensitive
cell line (MCF-7). In fact, most of MCF-7 cells
appeared to be negative for the LRP labelling and only
Plate 3. Intracellular DOX distribution in living MCF-7 and A549 cells detected by laser scanning confocal microscopy. (a) MCF-7 cells treated
with 2 mm DOX for 10 min showed a diﬀuse ﬂuorescent signal; (b) in contrast, A549 cells showed ﬂuorescent vesicular structures in the perinuclear
region. (c) After 30 min of treatment, nuclei of MCF-7 cells contained higher DOX amounts as compared to (d) A549 cells. (e,f) After 4 h of
treatment, DOX was located inside the nuclei and in the perinuclear region of both cell lines even if a higher ﬂuorescent signal could be detected in
MCF-7 cells, conﬁrming ﬂow cytometric determination. The colour represents the signal intensity with the pseudocolours. Black to white corre-
sponds to minimum to maximum intensity (800).
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a few cells displayed a weak ﬂuorescence (Plate 4c).
Conversely, most of A549 cells were LRP-positive, with
a punctate pattern of immunoﬂuorescent labelling
around the nuclei and in the cytoplasm (Plate 4d).
Similar results were obtained following incubation with
MAb LRP-42 (data not shown).
4. Discussion
Intrinsic drug resistance to anticancer agents is one of
the most serious obstacles to successful cancer chemo-
therapy (Dong et al., 1992). It is well known that cancer
cells with diﬀerent histotypes show signiﬁcant diﬀer-
ences in the response to the cytotoxic eﬀect of various
antineoplastic agents. Such diﬀerential drug sensitivity
depends on a number of cellular components and
metabolic pathways, most of which are not yet com-
pletely elucidated. To gain a better insight into the
mechanisms underlying the intrinsically resistant phe-
notype, two human cell lines, MCF-7 breast adeno-
carcinoma and A549 non small cell lung cancer
(NSCLC), which show diﬀerent sensitivity to DOX,
have been analysed.
Lung carcinoma cells actually exhibited a sponta-
neous resistance to drug treatment, which was about 40
times as high as breast cancer cells. Flow cytometric
analysis revealed that A549 cells accumulated lower
intracellular drug amounts following 4 h incubation
with DOX, while the observations performed by LSCM
on living cells evidenced marked diﬀerences in intracel-
lular DOX distribution between the two cell lines. These
ﬁndings are in agreement with the results of a previous
study (Dolﬁni et al., 1997), which showed a decreased
drug accumulation in a LoVo human colon adeno-
carcinoma cell clone characterized by low-level sponta-
neous resistance to DOX (LoVo 7) when compared to
the parental cell population (LoVo WT). Moreover,
several Authors have reported a decrease in the nuclear/
cytoplasmic ratios of DOX amount in a number of
resistant cell lines (Willingham et al., 1986; Meschini et
al., 1994; Arancia et al., 1998).
Plate 4. LRP expression and distribution in MCF-7 and A549 cells. (a) Immunoprecipitation analysis with MAb LRP-56 in A549 and in MCF-7
cells. Lysates were immunoprecipitated as described in Materials and methods with LRP-56 or with an irrelevant mouse antibody. No 110 kDa
protein was detected in the negative control (CN). Molecular weight is expressed in thousands. (b) Flow cytometric analysis after incubation of
samples with MAb LRP-56 and a goat anti-mouse IgG ﬂuorescein-conjugate secondary antibody. On the y-axis, protein content was expressed in
arbitrary units (A.U.) and calculated as the ratio of the MFC of labelled samples on the MFC of negative controls, obtained by incubating the cells
with mouse isotypic globulins. A549 showed to express higher levels of LRP than MFC-7 cells (*P<0.05). LSCM of (c) MCF-7 cells and (d) A549
cells after labelling with MAb LRP-56 revealed that breast cancer cells were quite negative while lung carcinoma cells showed a strong ﬂuorescent
signals arising from the cytoplasm (500).
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A close relationship between changes in intracellular
drug accumulation and distribution and the expression
and localization of diﬀerent drug transporters com-
monly implicated in drug resistance has been extensively
demonstrated (Schuurhuis et al., 1991; Molinari et al.,
1994, 1998; Dolﬁni et al., 1997). In our cell models,
analysis of P-gp and MRP1 expression by ﬂow cyto-
metry and confocal microscopy failed to detect any
signiﬁcant diﬀerence in the content of these proteins
between the two cell lines, suggesting that neither P-gp
nor MRP1 plays a major role in determining the
observed diﬀerences in drug accumulation and intracel-
lular distribution. In contrast, both ﬂow cytometry and
immunoprecipitation demonstrated higher levels of
LRP expression in unselected A549 cells, which showed
lower sensitivity to DOX treatment. Several experi-
mental ﬁndings indicate that LRP could participate in
cytoprotective processes preventing access of cytotoxic
drugs and xenobiotics to cytoplasmic and/or nuclear
targets (Izquierdo et al., 1996; Laurencot et al., 1997;
Kickhoefer et al., 1998; Dalton and Scheper, 1999).
Recently, Berger et al. (2000) demonstrated the presence
of LRP mRNA and protein in a number of untreated
NSCLC cell lines, suggesting that this drug transporter
might play an important role in the defensive response
of NSCLC cells against chemotherapeutic drugs. More-
over, direct involvement of LRP in the occurrence of a
resistant phenotype to DOX was demonstrated in a
human colon carcinoma cell line, SW-620, which did
not express P-gp and MRP, but nevertheless developed
resistance to DOX by upregulating LRP expression fol-
lowing treatment with sodium butyrate (Kitazono et al.,
2001). In this cell line, LRP was shown to mediate DOX
export from the nucleus to the cytoplasm, and its role in
resistance to DOX was conﬁrmed by the observation
that the new inhibitor PAK-104 P, which interferes with
drug transport by LRP as well as by P-gp and MRP1
(Shudo et al., 1990; Sumizawa et al., 1997), was able to
reverse, at least in part, the MDR phenotype in this P-
gp/MRP1-negative cell line.
Our confocal microscopic observations showed that
LRP colocalized with DOX in same vesicular structures
in the cytoplasm and in the perinuclear region, suggest-
ing that the role of this protein in MDR consist in
sequestering cytotoxic drugs away from the nucleus.
Previous studies by our group showed that in drug-
induced MDR cells P-gp was also localized in the Golgi
apparatus and in cytoplasmic vesicles (Molinari et al.,
1994) and had therefore been proposed to contribute to
cellular defense mechanisms against xenobiotics by
sequestering DOX within the cytoplasm.
The low level of LRP expression detected in MCF-7
cells, in complete agreement with the results of a num-
ber of previous studies (Izquierdo et al., 1996; Kic-
khoefer et al., 1998), might account for the
characteristic sensitivity displayed by breast tumor cells
to DOX treatment in vitro and possibly for the higher
rate of response of this tumor type to clinical treat-
ments. Further investigations will be required to identify
the mechanisms regulating LRP overexpression in
resistant cells; however, the results of the present study
indicate that LRP, together with an increasing number
of markers of intrinsic drug resistance, might provide
valuable clues as to the pattern of drug sensitivity of
individual tumors, thus helping to design more eﬀective
treatment protocols for the clinical management of
human malignancies.
Acknowledgements
We wish to thank Mr. L. Camilli for valuable techni-
cal assistance.
References
Alley, M.C., Scudiero, D.A., Monks, A., Hursey, M.L., Czerwinski,
M.J., Fine, D.L., Abbot, B.J., Mayo, J.G., Shoemaker, R.H., Boyd,
M.R., 1988. Feasibility of drug screening with panels of human
tumor cell lines using a microculture tetrazolium assay. Cancer
Research 48, 589–601.
Arancia, G., Calcabrini, A., Meschini, S., Molinari, A., 1998. Intra-
cellular distribution of anthracyclines in drug resistant cells. Cyto-
technology 27, 95–111.
Berger, W., Elbling, L., Hauptmann, E., Micksche, M., 1997. Expres-
sion of multidrug resistance-associated protein (MRP) and che-
moresistance of human non-small-cell lung cancer cells.
International Journal of Cancer 73, 84–93.
Berger, W., Elbling, L., Micksche, M., 2000. Expression of the major
vault protein L. R. P. in human non-small-cell lung cancer cells:
activation by short-term exposure to antineoplastic drugs. Interna-
tional Journal of Cancer 88, 293–300.
Childs, S., Ling, V., 1994. The M. D. R. superfamily of genes and its
biological implications. In: De Vita, V.T., Helleman, S., Rosenberg,
S.A. (Eds.), Important Advances in Oncology. J.B. Lippincott
Company, Philadelphia, pp. 21–36.
Clarke, R., Dickson, R.B., Bru¨nner, N., 1990. The process of malig-
nant progression in human breast cancer. Annals of Oncology 1,
401–407.
Cole, S.P.C., Bhardway, G., Gerlach, J.H., Mackie, J.E., Grant, C.E.,
Almquist, K.C., Stewart, A.J., Kurz, E.U., Duncan, A.M.V., Dee-
ley, R.G., 1992. Overexpression of a transporter gene in a multidrug
resistant human lung cancer cell line. Science (Wash 258, 1650–
1654.
Dalton, W.S., Scheper, R.J., 1999. Lung resistance-related protein:
determining its role in multidrug resistance. Journal of the National
Cancer Institute 91, 1604–1605.
Dietel, M., Arps, H., Lage, H., Niendorf, A., 1990. Membrane vesicle
formation due to acquired mitoxantrone resistance in human gastric
carcinoma cell line PG85–257. Cancer Research 50, 6100–6106.
Dolﬁni, E., Dasdia, T., Arancia, G., Molinari, A., Calcabrini, A.,
Scheper, R.J., Flens, M.J., Gariboldi, M.B., Monti, E., 1997. Char-
acterization of a clonal human colon adenocarcinoma line intrinsi-
cally resistant to doxorubicin. British Journal of Cancer 76, 67–76.
Dong, Z., Ward, N.E., Fan, D., Gupta, K., O’Brian, C.A., 1992. In
vitro model for intrinsic drug resistance: eﬀects of protein kinase C
activators on the chemosensitivity of cultured human colon cancer
cells. Molecular Pharmacology 39, 563–569.
S. Meschini et al. / Toxicology in Vitro 16 (2002) 389–398 397
Doyle, L.A., 1993. Mechanisms of drug resistance in human lung
cancer cells. Seminars in Oncology 20, 326–337.
Flens, M.J., Izquierdo, M.A., Scheﬀer, G.L., Schroeijers, A.B., Fritz,
J.M., Meijer, C.J.L.M., Scheper, R.J., Zaman, G.J.R., 1994. Immuno-
chemical detection of M. R. P. in human multidrug-resistant tumor
cells by monoclonal antibodies. Cancer Research 54, 4557–4563.
Gottesman, M.M., Pastan, I., 1993. Biochemistry of multidrug resis-
tance mediated by the multidrug transporter. Annual Reviews of
Biochemistry 62, 385–427.
Izquierdo, M.A., Scheﬀer, G.L., Flens, M.J., Giaccone, G., Broxter-
man, H.J., Meijer, C.J., van der Valk, P., Scheper, R.J., 1996. Broad
distribution of the multidrug resistance-related vault lung resistance
protein in normal human tissues and tumours. American Journal of
Pathology 148, 877–887.
Kedersha, N.L., Miquel, M.C., Bittner, D., Rome, L.H., 1990. Vaults.
II. Ribonucleoprotein structures are highly conserved among higher
and lower eukaryotes. Journal of Cell Biology 110, 895–901.
Kickhoefer, W.A., Rajavel, K.S., Scheﬀer, G.L., Dalton, W.S., Sche-
per, R.J., Rome, L.H., 1998. Vaults are up-regulated in multidrug-
resistant cancer cell lines. The Journal of Biological Chemistry 273,
8971–8974.
Kitazono, M., Okumura, H., Ikeda, R., Sumizawa, T., Furukawa, T.,
Nagayama, S., Seto, K., Aikou, T., Akiyama, S., 2001. Reversal of
L. P. R.- associated drug resistance in colon carcinoma SW-620
cells. International Journal of Cancer 91, 126–131.
Laurencot, C.M., Scheﬀer, G.L., Scheper, R.J., Shoemaker, R.H.,
1997. Increased L. R. P. mRNA expression is associated with the
M. D. R. phenotype in intrinsically resistant human cancer cell
lines. International Journal of Cancer 72, 1021–1026.
Leonessa, F., Boulay, V., Wright, A., Thompson, E.W., Bru¨nner, N.,
Clarke, R., 1992. The biology of breast tumour progression. Acta
Oncologica 31, 115–123.
Meschini, S., Calcabrini, A., Monti, E., Del, Bufalo., Stringaro, D.,
Dolﬁni, A., Arancia, E.G., 2000. Intracellular P-glycoprotein
expression is associated with the intrinsic multidrug resistance phe-
notype in human colon adenocarcinoma cells. International Journal
of Cancer 87, 615–628.
Meschini, S., Molinari, A., Calcabrini, A., Citro, G., Arancia, G.,
1994. Intracellular localization of the antitumor drug adriamycin in
living cultured cells: a confocal microscopy study. Journal of
Microscopy 176, 204–210.
Molinari, A., Calcabrini, A., Meschini, S., Stringaro, A., Del, Bufalo.,
Cianfriglia, D., Arancia, M.G., 1998. Detection of P-glycoprotein in
the Golgi apparatus of drug-untreated human melanoma cells.
International Journal of Cancer 75, 885–893.
Molinari, A., Cianfriglia, M., Meschini, S., Calcabrini, A., Arancia,
G., 1994. P-glycoprotein expression in the Golgi apparatus of
multidrug-resistant cells. International Journal of Cancer 59, 789–
795.
Scheﬀer, G.L., Wijngaard, P.L.J., Flens, M.J., Izquierdo, M.A., Slo-
vak, M.L., Pinedo, H.M., Meijer, C.J.L.M., Clevers, H.C., Scheper,
R.J., 1995. The drug resistance-related protein L. R. P. is the human
major vault protein. Nature Medicine 1, 578–582.
Scheper, R.J., Broxterman, H.J., Scheﬀer, G.L., Kaaiijk, P., Dalton,
W.S., van, Heijningen, T.H., van, Kalken, C.K., Slovak, M.L., de,
Vries, E.G., van der, Valk, P., Meijer, C.J.L.M., Pinedo, H.M.,
1993. Overexpression of a M(r) 110,000 vesicular protein in non P-
glycoprotein-mediated multidrug resistance. Cancer Research 53,
1475–1479.
Schuurhuis, G.J., Broxterman, H.J., de, Lange, J.H.M., Pinedo, H.M.,
van, Heijningen, T.H., Kuiper, C.M., Scheﬀer, G.L., Scheper, R.J,
van, Kalken, C.K., Baak, M., Lunkelma, J., 1991. Early multidrug
resistance, deﬁned by changes in intracellular doxorubicin distribu-
tion, independent of P-glycoprotein. British Journal of Cancer 64,
857–861.
Shapiro, A.B., Ling, V., 1995. Using puriﬁed P-glycoprotein to
understand multidrug resistance. Journal of Bioenergetics and Bio-
membranes 27, 7–13.
Shudo, N., Mizoguchi, T., Kiyosue, T., Arita, M., Yoshimura, A.,
Seto, K., Sakoda, R., Akiyama, S., 1990. Two pyridine analogues
with more eﬀective ability to reverse multidrug resistance and with
lower calcium channel blocking activity than their dihydropyridine
counterparts. Cancer Research 50, 3055–3061.
Sumizawa, T., Chen, Z.S., Chuman, Y., Seto, K., Furukawa, T.,
Haraguchi, M., Tani, A., Shudo, N., Akiyama, S.I., 1997. Reversal
of multidrug resistance-associated protein-mediated drug resistance
by the pyridine analog P. A. K.-104P. Molecular Pharmacology 51,
399–405.
Willingham, M.C., Cornwell, M.M., Cardarelli, C.O., Gottesman,
M.M., Pastan, I., 1986. Single cell analysis of daunomycin uptake
and eﬄux in multidrug-resistant and -sensitive KB cells: eﬀect of
verapamil and other drugs. Cancer Research 46, 5941–5946.
398 S. Meschini et al. / Toxicology in Vitro 16 (2002) 389–398
